Quest Q2 Revenues Flat | GenomeWeb

NEW YORK (GenomeWeb News) – Quest Diagnostics today reported that second-quarter revenues were essentially flat compared to a year ago.

For the three months ended June 30, revenues inched up .5 percent year over year to $1.91 billion, up from $1.90 billion, missing Wall Street estimates of $1.94 billion.

Clinical testing revenues during the quarter inched up .7 percent, Quest said.

SG&A spending was down 5 percent to $440.8 million from $462.8 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.